Prognostic significance of HALP score in İdiopathic Pulmonary Fibrosis-related mortality

Mustafa Çolak; Hikmet Çoban; Nurhan Sarıoğlu; Merve Yumrukuz Şenel; Fuat Erel

doi:10.36141/svdld.v42i2.16003

Authors

Mustafa Çolak Department of Chest Disease, University of Balikesir, Turkey https://orcid.org/0000-0002-8458-3535
Hikmet Çoban Department of Chest Disease, University of Balikesir, Turkey https://orcid.org/0000-0001-6730-9932
Nurhan Sarıoğlu Department of Chest Disease, University of Balikesir, Turkey https://orcid.org/0000-0002-5180-9649
Merve Yumrukuz Şenel Department of Chest Disease, University of Balikesir, Turkey https://orcid.org/0000-0003-0205-5075
Fuat Erel Department of Chest Disease, University of Balikesir, Turkey https://orcid.org/0000-0002-4788-8161

Keywords:

HALP score, İdiopathic pulmonary fibrosis, mortality, prognostic factors, biomarkers

Abstract

Background and aim: To investigate the prognostic value of the HALP (Hemoglobin, Albumin, Lymphocyte, and Platelet) score for mortality in patients with Idiopathic Pulmonary Fibrosis (IPF).

Methods: From November 2020, 39 patients with IPF were followed for a duration of 3 years. At the end of 3 years, the relationship between the initial HALP score and mortality was investigated.

Results: Thirty-nine patients diagnosed with IPF were included in the study, 30 of whom were male. The average age of all patients was 68.79±7.08. At the end of the three-year follow-up period, 12 patients (33.3%) had died. When comparing patients who died and those who survived at the end of three years; significant differences were found in age, neutrophil, albumin, HALP score, FEV₁%_,FVC%, DLCO%, GAP score, and 6 MWD. ROC analysis for the HALP score's predictive value for mortality yielded an AUC of 0.743 and p=0.011. For a cut-off value of HALP≤30.5, p=0.01, sensitivity and specificity were 61.54% and 92.31%, respectively. Multivariate analysis for predicting mortality found HALP≤30.50 as a significant risk factor (p=0.046). An increase of one monad at the HALP cut-off (≤30.50) score level reduced the risk of death by 9.57 times. It was observed that FVC%, DLCO% and 6 MWD were not risk factors in predicting mortality. (p=0.30, p=0.08, p=0.07).

Conclusions: Our study suggests that the HALP score may serve as a negative prognostic biomarker that can be used to predict mortality in cases with IPF.

References

1. Polat G, Özdemir Ö, Ermin S, Serçe Unat D, Demirci Üçsular F. Predictive factors of mortality in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a novel prognostic scoring system. Sarcoidosis Vasc Diffuse Lung Dis. 2024;41(2):e2024021. doi: 10.36141/svdld.v41i2.13779.

2. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811-23. doi: 10.1056/NEJMra1705751.

3. Kocaoglu S, Alatli T. The efficiency of the HALP score and the modified HALP score in predicting mortality in patients with acute heart failure presenting to the emergency department. J Coll Physicians Surg Pak. 2022;32(6):706-11. doi: 10.29271/jcpsp.2022.06.706.

4. Kayıkçı A, Alatas F, Alatas IO, Yıldırım H, Ozen H. The role of biomarkers in the diagnosis and treatment follow-up of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2024;41(2):e2024015. doi: 10.36141/svdld.v41i2.15454.

5. Maher TM. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev. 2013;22(128):148-52. doi: 10.1183/09059180.00000913.

6. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824. doi: 10.1164/rccm.2009-040GL.

7. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208(7):1339-50. doi: 10.1084/jem.20110551.

8. Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79-91. doi: 10.1016/j.rmed.2018.12.015.

9. Tian M, Li Y, Wang X, et al. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is associated with poor outcome of acute ischemic stroke. Front Neurol. 2021;11:610318. doi: 10.3389/fneur.2020.610318.

10. Xu H, Zheng X, Ai J, Yang L. Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: a systematic review and meta-analysis of 13,110 patients. Int Immunopharmacol. 2023;114:109496. doi: 10.1016/j.intimp.2022.109496.

11. Han H, Hu S, Du J. Predictive value of the hemoglobin-albumin-lymphocyte-platelet (HALP) index for ICU mortality in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Intern Emerg Med. 2023;18(1):85-96. doi: 10.1007/s11739-022-03132-4.

12. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.

13. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810-6. doi: 10.1164/rccm.200602-163OC.

14. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941-52. doi: 10.1016/S0140-6736(17)30866-8.

15. Benegas Urteaga M, Ramírez Ruz J, Sánchez González M. Idiopathic pulmonary fibrosis. Radiologia. 2022;64(Suppl 3):227-39. doi: 10.1016/j.rxeng.2022.10.009.

16. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-92. doi: 10.1056/NEJMoa1402582.

17. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82. doi: 10.1056/NEJMx150012.

18. Zheng Q, Cox IA, Campbell JA, et al. Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open Res. 2022;8(1):00591-2021. doi: 10.1183/23120541.00591-2021.

19. Fisher JH, Kolb M, Algamdi M, et al. Baseline characteristics and comorbidities in the Canadian Registry for Pulmonary Fibrosis. BMC Pulm Med. 2019;19(1):223. doi: 10.1186/s12890-019-0986-4.

20. Fernández Fabrellas E, Peris Sánchez R, Sabater Abad C, Juan Samper G. Prognosis and follow-up of idiopathic pulmonary fibrosis. Med Sci (Basel). 2018;6(2):51. doi: 10.3390/medsci6020051.

21. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-91. doi: 10.7326/0003-4819-156-10-201205150-00004.

22. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40(1):101-9. doi: 10.1183/09031936.00106011.

23. Zhao Z, Xu L. Prognostic significance of HALP score and combination of peripheral blood multiple indicators in patients with early breast cancer. Front Oncol. 2023;13:1253895. doi: 10.3389/fonc.2023.1253895.

24. Jiang P, Kong W, Gong C, et al. Predicting the recurrence of operable cervical cancer patients based on hemoglobin, albumin, lymphocyte, and platelet (HALP) score and classical clinicopathological parameters. J Inflamm Res. 2022;15:5265-81. doi: 10.2147/JIR.S383742.

25. Güç ZG, Alacacıoğlu A, Kalender ME, et al. HALP score and GNRI: simple and easily accessible indexes for predicting prognosis in advanced stage NSCLC patients. The İzmir oncology group study. Front Nutr. 2022;9:905292. doi: 10.3389/fnut.2022.905292.

26. Çolak M, Uçkun S, Çoban H, Sarıoğlu N, Erel F. Can the HALP score predict survival in severe COVID-19 pneumonia? Postepy Hig Med Dosw. 2023;77(1):182-7. doi: 10.2478/ahem-2023-0024.

27. Han H, Hu S, Du J. Predictive value of the hemoglobin-albumin-lymphocyte-platelet (HALP) index for ICU mortality in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Intern Emerg Med. 2023;18(1):85-96. doi: 10.1007/s11739-022-03132-4.